Haemonetics Co. (NYSE:HAE) Stock Holdings Raised by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. increased its position in shares of Haemonetics Co. (NYSE:HAE - Free Report) by 1.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 551,193 shares of the medical instruments supplier's stock after acquiring an additional 8,477 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 1.10% of Haemonetics worth $43,037,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Parkside Financial Bank & Trust boosted its position in Haemonetics by 25.6% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock worth $92,000 after acquiring an additional 240 shares during the last quarter. KBC Group NV boosted its position in Haemonetics by 54.6% during the fourth quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier's stock worth $157,000 after acquiring an additional 712 shares during the last quarter. iSAM Funds UK Ltd acquired a new stake in Haemonetics during the third quarter worth approximately $204,000. Versor Investments LP boosted its position in Haemonetics by 9.1% during the third quarter. Versor Investments LP now owns 3,600 shares of the medical instruments supplier's stock worth $289,000 after acquiring an additional 300 shares during the last quarter. Finally, Empowered Funds LLC acquired a new stake in Haemonetics during the fourth quarter worth approximately $319,000. Institutional investors and hedge funds own 99.67% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the stock. JPMorgan Chase & Co. initiated coverage on shares of Haemonetics in a research report on Friday, December 6th. They set an "overweight" rating and a $116.00 target price on the stock. Bank of America lowered shares of Haemonetics from a "neutral" rating to an "underperform" rating and decreased their price target for the company from $95.00 to $68.00 in a report on Friday, February 7th. JMP Securities decreased their price target on shares of Haemonetics from $125.00 to $100.00 and set a "market outperform" rating on the stock in a report on Friday, February 7th. Barrington Research decreased their price target on shares of Haemonetics from $108.00 to $95.00 and set an "outperform" rating on the stock in a report on Friday, February 7th. Finally, Raymond James reiterated a "strong-buy" rating and issued a $115.00 price target (down previously from $120.00) on shares of Haemonetics in a report on Friday, February 7th. One analyst has rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Haemonetics has an average rating of "Moderate Buy" and an average price target of $101.22.

Remove Ads

Haemonetics Stock Down 0.2 %

Haemonetics stock traded down $0.11 during midday trading on Tuesday, hitting $64.69. 683,438 shares of the stock were exchanged, compared to its average volume of 647,177. Haemonetics Co. has a 1 year low of $58.80 and a 1 year high of $97.97. The firm has a market cap of $3.25 billion, a P/E ratio of 25.47, a P/E/G ratio of 1.11 and a beta of 0.43. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.97 and a quick ratio of 2.55. The company has a 50 day moving average price of $68.33 and a two-hundred day moving average price of $75.34.

Haemonetics (NYSE:HAE - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. On average, sell-side analysts predict that Haemonetics Co. will post 4.55 earnings per share for the current fiscal year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.